LU92446I2 - Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium - Google Patents

Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium

Info

Publication number
LU92446I2
LU92446I2 LU92446C LU92446C LU92446I2 LU 92446 I2 LU92446 I2 LU 92446I2 LU 92446 C LU92446 C LU 92446C LU 92446 C LU92446 C LU 92446C LU 92446 I2 LU92446 I2 LU 92446I2
Authority
LU
Luxembourg
Prior art keywords
dolutegravir
solvate
pharmaceutically acceptable
acceptable salt
including sodium
Prior art date
Application number
LU92446C
Other languages
English (en)
Original Assignee
Shionogi & Co
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92446(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co, Viiv Healthcare Co filed Critical Shionogi & Co
Publication of LU92446I2 publication Critical patent/LU92446I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92446C 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium LU92446I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (fr) 2005-04-28 2006-04-28 Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih

Publications (1)

Publication Number Publication Date
LU92446I2 true LU92446I2 (fr) 2015-10-29

Family

ID=37215098

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92446C LU92446I2 (fr) 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU00210C LUC00210I2 (fr) 2005-04-28 2021-06-15

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU00210C LUC00210I2 (fr) 2005-04-28 2021-06-15

Country Status (29)

Country Link
US (21) US8129385B2 (fr)
EP (9) EP3187226A1 (fr)
JP (2) JP4295353B2 (fr)
KR (4) KR101504998B1 (fr)
AU (1) AU2006239177B8 (fr)
BR (1) BRPI0610030B8 (fr)
CA (1) CA2606282C (fr)
CY (6) CY1115151T1 (fr)
DK (6) DK1874117T3 (fr)
EA (1) EA014162B1 (fr)
ES (7) ES2437268T3 (fr)
FI (1) FIC20210017I1 (fr)
FR (1) FR14C0041I2 (fr)
HK (4) HK1107227A1 (fr)
HU (6) HUE056603T2 (fr)
IL (4) IL186555A (fr)
LT (4) LT3045206T (fr)
LU (2) LU92446I2 (fr)
MA (1) MA29460B1 (fr)
MX (2) MX302718B (fr)
NL (2) NL300676I2 (fr)
NO (5) NO339525B1 (fr)
NZ (1) NZ562339A (fr)
PL (5) PL1874117T3 (fr)
PT (5) PT3284520T (fr)
SI (6) SI3372281T1 (fr)
TW (1) TWI378931B (fr)
VN (1) VN34404A1 (fr)
WO (1) WO2006116764A1 (fr)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551178C (fr) 2003-12-24 2012-11-06 Biota Scientific Management Pty Ltd Agents polycycliques pour le traitement d'infections par le virus syncytial respiratoire
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
PT3284520T (pt) 2005-04-28 2019-09-10 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv
CA2607151C (fr) 2005-05-10 2012-06-19 Merck & Co., Inc. Inhibiteurs de l'integrase du vih
CA2622639C (fr) 2005-10-04 2012-01-03 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibiteurs de l'integrase du vih
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
JP5269085B2 (ja) 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
PL2220076T3 (pl) 2007-11-15 2012-09-28 Gilead Sciences Inc Inhibitory replikacji ludzkiego wirusa niedoboru odporności
UA100250C2 (uk) 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Інгібітори реплікації вірусу імунодефіциту людини
JP5551697B2 (ja) * 2008-07-25 2014-07-16 ビーブ・ヘルスケア・カンパニー 化合物
WO2010011815A1 (fr) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
WO2010011818A1 (fr) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
ES2448766T3 (es) 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
CN103951643B (zh) 2008-07-25 2015-12-09 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
JP5629268B2 (ja) * 2008-12-11 2014-11-19 塩野義製薬株式会社 マルトールエーテルの製造方法および中間体
KR101847887B1 (ko) 2008-12-11 2018-04-11 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
US8552187B2 (en) * 2008-12-11 2013-10-08 Shionogi & Co., Ltd. Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2444400B1 (fr) 2009-06-15 2018-03-28 Shionogi&Co., Ltd. Dérivé de carbamoylpyridone polycyclique substituée
WO2011011483A1 (fr) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Composés chimiques
CN102574854B (zh) 2009-10-13 2014-04-16 伊兰科动物健康爱尔兰有限公司 大环整合酶抑制剂
KR101883750B1 (ko) * 2010-01-27 2018-07-31 비이브 헬쓰케어 컴퍼니 항바이러스 치료
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
BR112012021595A2 (pt) 2010-02-26 2017-02-21 Japan Tobacco Inc "composto derivado de 1,3,4,8-tetra-hidro-2h-pirido[1,2-a]pirazina, suas composições, seus usos, agente anti-hiv, inibidor da integrase de hiv e embalagem comercial"
TWI582097B (zh) * 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
WO2011129095A1 (fr) * 2010-04-12 2011-10-20 塩野義製薬株式会社 Dérivé de pyridone ayant une activité inhibitrice de l'intégrase
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
DK3456721T3 (da) * 2010-08-05 2021-04-26 Shionogi & Co Fremgangsmåde til at fremstille forbindelser som har hiv-integrase-inhiberende aktivitet.
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
RU2608519C2 (ru) 2010-09-24 2017-01-19 Шионоги энд Ко. Лтд. Пролекарственная форма замещенного полициклического производного карбамоилпиридона
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
ES2613180T3 (es) 2011-09-14 2017-05-23 Mapi Pharma Limited Forma amorfa de la sal sódica dolutegravir
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PL3738434T3 (pl) 2011-12-28 2024-03-04 Global Blood Therapeutics, Inc. Związki pośrednie do otrzymywania podstawionych związków benzaldehydowych i sposoby ich zastosowania do zwiększania natlenienia tkanek
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
SG11201504857SA (en) * 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221380A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
EP2767272A1 (fr) 2013-02-18 2014-08-20 Ratiopharm GmbH Forme posologique pharmaceutique solide de dolutegravir
WO2014125124A1 (fr) 2013-02-18 2014-08-21 Ratiopharm Gmbh Forme galénique pharmaceutique solide de dolutegravir
WO2014128545A2 (fr) 2013-02-19 2014-08-28 Aurobindo Pharma Limited Procédé amélioré pour la préparation du dolutégravir
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (fr) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902711C (fr) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Derives de pyridinyl-6-methoxy-2-hydroxybenzaldehyde substitues et compositions pharmaceutiques de ceux-ci pour utilisation dans la modulation de l'hemoglobine
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
KR20190041548A (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EP2986291B1 (fr) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
WO2014200880A1 (fr) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2015001572A2 (fr) * 2013-07-04 2015-01-08 Hetero Research Foundation Procédé pour la préparation d'intermédiaire de dolutégravir
CA2916993C (fr) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Composes polycycliques-carbomoylpyridone et leur utilisation pharmaceutique
NO2865735T3 (fr) * 2013-07-12 2018-07-21
US9856270B2 (en) * 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (fr) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Procédé de préparation de dolutégravir et ses intermédiaires
WO2015039348A1 (fr) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
SG11201602217XA (en) 2013-09-27 2016-04-28 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (fr) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
WO2015092752A1 (fr) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Nouvelle forme cristalline de dolutegravir sodium
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
EP3096763B1 (fr) 2014-01-21 2019-12-25 Laurus Labs Limited Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables
PE20160179A1 (es) 2014-02-07 2016-05-20 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
CN106866701B (zh) * 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (fr) 2014-03-20 2015-09-24 Cipla Limited Composition pharmaceutique
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
NO2717902T3 (fr) * 2014-06-20 2018-06-23
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JPWO2016027879A1 (ja) * 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
EP3203995A4 (fr) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska Compositions et méthodes d'administration d'agents thérapeutiques
WO2016092527A1 (fr) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited Procédé de préparation de dolutégravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (fr) 2014-12-24 2016-06-30 Ratiopharm Gmbh Formes solides de dolutégravir sodique
EP3045461A1 (fr) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Procédés de préparation de Dolutégravir et de ses analogues
WO2016125192A2 (fr) 2015-02-06 2016-08-11 Mylan Laboratories Limited Procédé de préparation de dolutégravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
US10081647B2 (en) * 2015-03-26 2018-09-25 Merck Sharp & Dohme Corp. Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3277691T3 (pl) 2015-04-02 2019-07-31 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
LT3428170T (lt) * 2015-04-28 2021-02-10 Shionogi & Co., Ltd Policiklinis piridono darinys nuo gripo ir jo provaistas
WO2016187788A1 (fr) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
US10597404B2 (en) 2015-08-19 2020-03-24 Laurus Labs Ltd. Polymorphs of dolutegravir and salts thereof
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
WO2017087257A1 (fr) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
PT3394069T (pt) 2015-12-21 2019-08-30 Lupin Ltd Processo para a preparação de inibidores de integrase de vih
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
WO2017208105A1 (fr) 2016-05-30 2017-12-07 Lupin Limited Nouvelle forme cristalline de dolutégravir sodique
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
US11091483B2 (en) * 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
WO2018042332A1 (fr) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
US20190216725A1 (en) * 2016-09-21 2019-07-18 Merck Shapr & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018102634A1 (fr) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (fr) 2016-12-16 2018-06-21 Cipla Limited Nouveaux polymorphes et sels de dérivés de carbamoyle pyridone polycycliques
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
AU2018221379B2 (en) * 2017-02-16 2021-11-04 ViiV Healthcare UK (No.3) Limited Crystalline forms of cabotegravir sodium
EP3363802B1 (fr) * 2017-02-16 2019-11-20 Sandoz AG Forme cristalline du sel de sodium de cabotegravir
EP3655106A4 (fr) * 2017-07-18 2021-04-21 VIIV Healthcare Company Polythérapie
MX2020000790A (es) 2017-07-21 2020-11-11 Viiv Healthcare Co Pautas para el tratamiento de infecciones por el vih y sida.
US20210040116A1 (en) 2017-09-07 2021-02-11 Cipla Limited New Polymorphs of Dolutegravir Sodium
AR113748A1 (es) 2017-10-06 2020-06-10 Shionogi & Co Proceso estereoselectivo para preparar derivados de piridona policíclicos sustituidos
EP3737359A4 (fr) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska Promédicaments antiviraux et formulations de ceux-ci
WO2019159199A1 (fr) 2018-02-16 2019-08-22 Cipla Limited Procédé à flux continu pour la préparation de dérivés de carbamoylpyridone polycycliques à ingrédients pharmaceutiquement actifs et intermédiaires de ceux-ci
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
TW202323254A (zh) * 2018-05-31 2023-06-16 日商鹽野義製藥股份有限公司 多環性吡啶并三𠯤衍生物
US11649236B2 (en) 2018-05-31 2023-05-16 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative
AU2019277547A1 (en) * 2018-05-31 2021-01-14 Shionogi & Co., Ltd. Polycyclic pyridone derivative
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
WO2020072377A1 (fr) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
WO2020086555A1 (fr) 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Promédicaments antiviraux et nanoformulations de ceux-ci
PL3938047T3 (pl) 2019-03-22 2022-11-07 Gilead Sciences, Inc. Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
WO2021173522A1 (fr) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Composés tétracycliques pour le traitement d'une infection par le vih
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US20230321089A1 (en) 2020-09-01 2023-10-12 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
WO2022079739A1 (fr) 2020-10-14 2022-04-21 Cipla Limited Compositions à dose fixe de cabotégravir et de rilpivirine
EP4255472A2 (fr) 2020-12-07 2023-10-11 VIIV Healthcare Company Polythérapie
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
WO2022253294A1 (fr) 2021-06-03 2022-12-08 江苏恒瑞医药股份有限公司 Composé de pyridone ayant une activité inhibitrice d'intégrase et utilisation pharmaceutique de celui-ci
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (fr) 2021-12-03 2023-06-08 Viiv Healthcase Company Procédé de synthèse de (r)-3-aminobutan-1-ol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
US6093732A (en) 1997-12-22 2000-07-25 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
WO2001095905A1 (fr) † 2000-06-14 2001-12-20 Shionogi & Co., Ltd. Inhibiteur d'enzymes possedant deux ions metal divalents en tant que centres actifs
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
ES2287170T3 (es) 2000-10-12 2007-12-16 MERCK & CO., INC. Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
DK2266958T1 (da) 2001-08-10 2016-04-04 Shionogi & Co Antiviralt middel
MXPA04003932A (es) 2001-10-26 2004-06-18 Angeletti P Ist Richerche Bio Inhibidores de la hidroxipirimidinona carboxamida n-sustituida de la integrasa del virus de inmunodeficiencia humana.
WO2003035076A1 (fr) 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Inhibiteurs de l'integrase du vih a base de dihydroxypyrimidine carboxamide
CA2472372C (fr) 2002-01-17 2010-08-17 Melissa Egbertson Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
US7358249B2 (en) 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
CA2498111A1 (fr) 2002-09-11 2004-03-25 Merck & Co., Inc. Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
EP1578748B1 (fr) 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines et composes connexes convenant comme inhibiteurs de l'integrase du vih
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
US7812016B2 (en) 2003-05-13 2010-10-12 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
WO2005015927A1 (fr) * 2003-08-12 2005-02-17 Rachel Beijer Service de messages planifies
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
BRPI0507628A (pt) 2004-02-11 2007-07-03 Smithkline Beecham Corp composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
JP2007528394A (ja) † 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
EP1725554A1 (fr) 2004-03-09 2006-11-29 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Inhibiteurs de l'int grase du vih
EP1756114B1 (fr) 2004-05-07 2014-11-19 Merck Sharp & Dohme Corp. Inhibiteurs de l'integrase du vih
CA2634499A1 (fr) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones et procedes d'inhibition de l'integrase du vih
US7858788B2 (en) 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
EP1866313A1 (fr) 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Inhibiteurs de l`integrase du vih
PT3284520T (pt) * 2005-04-28 2019-09-10 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
WO2007019098A2 (fr) 2005-08-04 2007-02-15 Smithkline Beecham Corporation Inhibiteurs de l'integrase du vih
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity

Also Published As

Publication number Publication date
EA014162B1 (ru) 2010-10-29
US20120115875A1 (en) 2012-05-10
US8410103B2 (en) 2013-04-02
PL1874117T3 (pl) 2014-01-31
LT3284520T (lt) 2019-09-25
TWI378931B (en) 2012-12-11
CY1122052T1 (el) 2020-10-14
PL3045206T3 (pl) 2018-08-31
NL301109I2 (nl) 2021-09-15
PT3045206T (pt) 2018-07-05
DK3187225T3 (da) 2022-02-28
US9051337B2 (en) 2015-06-09
WO2006116764A1 (fr) 2006-11-02
CY1116331T1 (el) 2017-02-08
EP3045206B1 (fr) 2018-03-28
US20160304535A1 (en) 2016-10-20
FR14C0041I1 (fr) 2014-06-27
KR20160003889A (ko) 2016-01-11
PL2465580T3 (pl) 2014-05-30
KR101363875B1 (ko) 2014-02-21
IL186555A (en) 2016-10-31
EP3284519A8 (fr) 2018-04-18
CY1115151T1 (el) 2015-12-09
US9273065B2 (en) 2016-03-01
JP4295353B2 (ja) 2009-07-15
US20140200209A1 (en) 2014-07-17
BRPI0610030A2 (pt) 2011-10-11
JP2008540343A (ja) 2008-11-20
FR14C0041I2 (fr) 2015-11-13
US20170253616A1 (en) 2017-09-07
EP3187225A1 (fr) 2017-07-05
DK3372281T3 (da) 2021-09-27
SI1874117T1 (sl) 2014-01-31
EP1874117B8 (fr) 2014-03-12
US20150232479A1 (en) 2015-08-20
DK3284520T3 (da) 2019-09-16
US20130172559A1 (en) 2013-07-04
EP3187226A1 (fr) 2017-07-05
MA29460B1 (fr) 2008-05-02
EP3372281A1 (fr) 2018-09-12
ES2667868T5 (es) 2023-06-01
IL186555A0 (en) 2008-01-20
ES2892304T3 (es) 2022-02-03
PT3284520T (pt) 2019-09-10
US20170267693A1 (en) 2017-09-21
EP2527007A1 (fr) 2012-11-28
EP1874117A4 (fr) 2009-12-30
SI3372281T1 (sl) 2021-11-30
US20160207939A1 (en) 2016-07-21
NZ562339A (en) 2011-01-28
HUE056603T2 (hu) 2022-02-28
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
IL215788A0 (en) 2011-12-29
MX302718B (es) 2012-08-27
EP3187225B1 (fr) 2022-01-05
US20170145033A1 (en) 2017-05-25
US8129385B2 (en) 2012-03-06
ES2743531T3 (es) 2020-02-19
EP3045206B2 (fr) 2023-02-15
US20190284208A1 (en) 2019-09-19
AU2006239177A1 (en) 2006-11-02
EP1874117A1 (fr) 2008-01-09
HK1251191A1 (zh) 2019-01-25
NO340111B1 (no) 2017-03-13
US20220213121A1 (en) 2022-07-07
CY1124601T1 (el) 2022-07-22
NL301109I1 (nl) 2021-09-15
DK2465580T3 (en) 2014-03-10
US20170029438A1 (en) 2017-02-02
US20170209454A1 (en) 2017-07-27
DK1874117T3 (da) 2013-09-23
US20090318421A1 (en) 2009-12-24
LUC00210I2 (fr) 2022-10-07
NO2021018I1 (no) 2021-05-10
ES2667868T3 (es) 2018-05-14
NO20161315A1 (no) 2007-11-22
VN34404A1 (en) 2013-07-25
NO2023042I1 (no) 2023-11-08
EP2527007B1 (fr) 2016-03-30
KR101848819B1 (ko) 2018-04-16
LTC2465580I2 (fr) 2022-10-10
HUS2100022I1 (hu) 2021-07-28
CA2606282C (fr) 2016-04-26
IL225206A (en) 2017-11-30
CA2606282A1 (fr) 2006-11-02
ES2567197T3 (es) 2016-04-20
EP3284520A1 (fr) 2018-02-21
HUS1400039I1 (hu) 2016-08-29
PL3284520T3 (pl) 2020-01-31
LT3045206T (lt) 2018-06-11
PT3372281T (pt) 2021-10-14
MX2007013351A (es) 2008-01-21
CY2014024I2 (el) 2015-12-09
SI3187225T1 (sl) 2022-04-29
PT1874117E (pt) 2013-10-17
NO339525B1 (no) 2016-12-27
HUE044978T2 (hu) 2019-11-28
BRPI0610030B8 (pt) 2022-01-11
KR101580310B1 (ko) 2016-01-04
HK1172282A1 (en) 2013-04-19
US8778943B2 (en) 2014-07-15
HK1249742A1 (zh) 2018-11-09
PL3372281T3 (pl) 2021-12-27
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
NO20075165L (no) 2007-11-22
US20170224695A1 (en) 2017-08-10
US11267823B2 (en) 2022-03-08
AU2006239177B2 (en) 2011-10-20
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
EP3045206A1 (fr) 2016-07-20
SI2465580T1 (sl) 2014-04-30
BRPI0610030B1 (pt) 2020-09-15
EP2465580A1 (fr) 2012-06-20
US20170260203A1 (en) 2017-09-14
ES2906792T3 (es) 2022-04-20
NO2017010I2 (no) 2017-03-27
LTPA2021512I1 (fr) 2021-07-12
HUS2100023I1 (hu) 2021-07-28
JP2009079058A (ja) 2009-04-16
ES2437268T3 (es) 2014-01-09
KR101504998B1 (ko) 2015-03-23
EA200702080A1 (ru) 2008-04-28
EP3284520B1 (fr) 2019-06-05
SI3045206T1 (en) 2018-07-31
ES2446324T3 (es) 2014-03-07
EP2465580B1 (fr) 2013-12-18
EP1874117B1 (fr) 2013-08-28
EP3284519A1 (fr) 2018-02-21
TW200716635A (en) 2007-05-01
US20170224694A1 (en) 2017-08-10
US20190152990A1 (en) 2019-05-23
IL225207A (en) 2017-11-30
US20200339598A1 (en) 2020-10-29
MX312216B (en) 2013-08-12
CY2014024I1 (el) 2015-12-09
CY1120345T1 (el) 2019-07-10
AU2006239177B8 (en) 2012-02-16
US20160137666A1 (en) 2016-05-19
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
KR20140097438A (ko) 2014-08-06
FIC20210017I1 (fi) 2021-06-10
HUE037795T2 (hu) 2018-09-28
SI3284520T1 (sl) 2019-10-30
NO2017010I1 (no) 2017-03-27
EP3372281B1 (fr) 2021-07-07
NL300676I2 (fr) 2016-10-11

Similar Documents

Publication Publication Date Title
LU92446I2 (fr) Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92568I2 (fr) Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
LU92702I2 (fr) Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
LU92137I2 (fr) Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
LU93180I2 (fr) Alirocumab ou un dérivé pharmaceutiquement acceptable de celui-ci (PRALUENT)
LU93312I2 (fr) Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate
FIC20240007I1 (fi) Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola
NL301106I2 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
LU92785I2 (fr) Céritinib ou un sel pharamceutiquement acceptable de celui-ci
NO2018016I2 (no) Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
NO2013008I2 (no) Krizotinib eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav
LU92512I2 (fr) Afoxolaner, ou un oxyde nitrique de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
NO2016016I1 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
LU91962I2 (fr) Azilsartan medoxomil (INN) et un de ses sels pharmaceutiquement acceptable, y compris le sel de potassium
GB0624471D0 (en) Merocyanine Derivatives
IL190608A0 (en) 5-(arylsulfonyl)-pyrazolopiperidines
FI20055187A0 (fi) Laitteisto seinien poimimiseksi